Cite
HARVARD Citation
Rudin, C. et al. (2023). Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors. Journal for immunotherapy of cancer. 11 (1), p. . [Online].